Management of CBD Stones At Laparoscopic Cholecystectomy

• Conditions: Choledocholithiasis; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12605000040662
• Lead Sponsor: Sydney West Area Health Service

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-07-25
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 340

Inclusion Criteria

The patient must be able to give informed consent preoperatively (i.e. elective procedures only). Patients at higher than normal risk of having CBD stones identified at OC: a CBD stone identified at ultrasound; a wide CBD (>6mm) at ultrasound; previous, recent, current cholangitis, jaundice, or biliary pancreatitis; abnormal AST and ALT levels (>2 times normal).

Exclusion Criteria

Pregnancy at time of surgery. Patients not fit for surgery. For example: those with acute cholecystitis or persistent obstructive jaundice; patients who have had a previous ERCP and sphincterotomy; those in whom intervention was not technically possible (eg. previous Billroth II gastrectomy).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety of facilitated ERCP compared to conventional unfacilitated ERCP[Assessed by the incidence of pancreatitis post ERCP]